Septerna (SEPN) Free Cash Flow (2023 - 2026)
Septerna's quarterly Free Cash Flow came in at -$26.5 million in Q1 2026, down 11.55% year-on-year from -$29.9 million in Q1 2025, and down 75.81% quarter-over-quarter from -$15.1 million in Q4 2025.
Septerna has reported Free Cash Flow for 4 years, with the latest figure at -$26.5 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 11.55% year-over-year to -$26.5 million; the trailing twelve-month figure through Mar 2026 stood at $106.9 million (up 241.03% YoY), and the FY2025 full-year result was $109.7 million, up 257.63% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$26.5 million, down from -$15.1 million in the prior quarter.
- The five-year high for Free Cash Flow was $168.8 million in Q3 2025, with the low at -$26.5 million in Q1 2026.
- Average Free Cash Flow over 4 years is $359700.0, with a median of -$17.4 million recorded in 2024.
- Year-over-year, Free Cash Flow tumbled 114.93% in 2024 and surged 1070.53% in 2025.
- Tracing SEPN's Free Cash Flow over 4 years: stood at -$10.0 million in 2023, then sank by 114.93% to -$21.6 million in 2024, then soared by 30.21% to -$15.1 million in 2025, then slumped by 75.81% to -$26.5 million in 2026.
- The last three Free Cash Flow figures came in at -$26.5 million (Q1 2026), -$15.1 million (Q4 2025), and $168.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - | -26.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.47 Mn |
| Mar 31, 2026 | -26.47 Mn |
| Dec 31, 2025 | -15.05 Mn |
| Dec 31, 2025 | -15.05 Mn |
| Sep 30, 2025 | 168.79 Mn |
| Sep 30, 2025 | 168.79 Mn |
| Jun 30, 2025 | -20.35 Mn |
| Jun 30, 2025 | -20.35 Mn |
| Mar 31, 2025 | -23.73 Mn |
| Mar 31, 2025 | -23.73 Mn |
| Dec 31, 2024 | -21.57 Mn |
| Dec 31, 2024 | -21.57 Mn |
| Sep 30, 2024 | -17.39 Mn |
| Sep 30, 2024 | -17.39 Mn |
| Jun 30, 2024 | -13.14 Mn |
| Jun 30, 2024 | -13.14 Mn |
| Mar 31, 2024 | -17.48 Mn |
| Mar 31, 2024 | -17.48 Mn |
| Dec 31, 2023 | -10.04 Mn |
| Dec 31, 2023 | -10.04 Mn |